Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Diluted Average): 2017-2024

Historic Shares Outstanding (Diluted Average) for Coherus Oncology (CHRS) over the last 8 years, with Dec 2024 value amounting to $114.8 million.

  • Coherus Oncology's Shares Outstanding (Diluted Average) rose 0.88% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 0.88%. This contributed to the annual value of $114.8 million for FY2024, which is 21.95% up from last year.
  • Per Coherus Oncology's latest filing, its Shares Outstanding (Diluted Average) stood at $114.8 million for FY2024, which was up 21.95% from $94.2 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Diluted Average) peaked at $114.8 million during FY2024, and registered a low of $75.4 million during FY2021.
  • Over the past 3 years, Coherus Oncology's median Shares Outstanding (Diluted Average) value was $94.2 million (recorded in 2023), while the average stood at $95.5 million.
  • As far as peak fluctuations go, Coherus Oncology's Shares Outstanding (Diluted Average) fell by 9.63% in 2021, and later increased by 21.95% in 2024.
  • Coherus Oncology's Shares Outstanding (Diluted Average) (Yearly) stood at $83.5 million in 2020, then declined by 9.63% to $75.4 million in 2021, then increased by 2.89% to $77.6 million in 2022, then rose by 21.30% to $94.2 million in 2023, then climbed by 21.95% to $114.8 million in 2024.